Immune thrombocytopenia (ITP) is a chronic autoimmune disorder associated with platelet destruction and increased bleeding risk, substantial economic burden, and impairment of health-related quality ...
For the first time, scientists have used a modern cell therapy called CAR-T to treat a patient with three different ...
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or ...
Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...
The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.
Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that ...
The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...
A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...
Introduction Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent ...
(ORLANDO, Dec. 9, 2025) Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results